Piper Sandler Maintains Neutral on Neogen, Raises Price Target to $17

Piper Sandler analyst David Westenberg maintains Neogen (NASDAQ:NEOG) with a Neutral and raises the price target from $14 to $17.

byBenzinga Newsdesk

December 15, 2022

1 minute read

Piper Sandler analyst David Westenberg maintains Neogen (NASDAQ:NEOG) with a Neutral and raises the price target from $14 to $17.

Truist Securities Maintains Buy on Insperity, Raises Price Target to $125

By Benzinga Newsdesk

Today, 11:16 AM

Truist Securities analyst Tobey Sommer maintains Insperity (NYSE:NSP) with a Buy and raises the price target from $115 to $125.

NSP

FDA
News

Adial Pharmaceuticals Announces Greater Than 50% Of Patients Expected To Complete ONWARD Phase 3 Trial Of AD04 For Treatment Of Alcohol Use Disorder Have Completed Full 24-Week Treatment Period; Says Trial Completion Anticipated Q1 2022

By Benzinga Newsdesk

Today, 11:16 AM

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of

ADIL

Analyst Ratings

Where Apellis Pharmaceuticals Stands With Analysts

By Benzinga Insights

Today, 11:16 AM

Analysts have provided the following ratings for Apellis Pharmaceuticals (NASDAQ:APLS) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago

APLS

Oil Jumps Over 3% As OPEC+ Meet Eyed: Analysts Say This Is The Bare Minimum Supply Cut For Markets To Care

By Bhavik Nair

Today, 11:16 AM

Oil prices soared over 3% on Monday morning in Asian trade after reports indicated the Organization of the Petroleum Exporting Countries and its allies (OPEC+) are likely to consider an output cut of over a million barrel

BNO

Piper Sandler Maintains Neutral on Neogen, Raises Price Target to $17

Related Posts

Truist Securities Maintains Buy on Insperity, Raises Price Target to $125

Adial Pharmaceuticals Announces Greater Than 50% Of Patients Expected To Complete ONWARD Phase 3 Trial Of AD04 For Treatment Of Alcohol Use Disorder Have Completed Full 24-Week Treatment Period; Says Trial Completion Anticipated Q1 2022

Where Apellis Pharmaceuticals Stands With Analysts

Oil Jumps Over 3% As OPEC+ Meet Eyed: Analysts Say This Is The Bare Minimum Supply Cut For Markets To Care